GoodRx reports seven ways to save on prescription costs with Medicare Part D, including state resources, generic medications, ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

The savings go into effect in 2027 and are expected to save billions for government health program.

The cuts stem from the Inflation Reduction Act, not Trump’s “most favored nation” approach, and apply to what Medicare pays ...

Upcoming data from Novo Nordisk A/S (NYSE: NVO) early next month could offer the clearest signal yet on whether GLP-1 medicines — widely used for diabetes and weight loss — can also slow the ...

FDA approves first oral GLP-1 agonist to lower heart attack and stroke risk in diabetics SOUL trial shows 14% drop in major cardiovascular events with Rybelsus Targets arterial inflammation and ...

Rybelsus (semaglutide) is a brand-name oral tablet prescribed to help manage blood sugar levels and reduce the risk of certain cardiovascular problems in adults with type 2 diabetes. When taking your ...

Rybelsus is now also indicated for cardiovascular risk reduction in adults with Type 2 diabetes who are at high risk, including those who have not had a prior CV event. This new indication makes ...

WASHINGTON — President Trump announced Thursday that two major pharmaceutical companies will be lowering the cost of popular GLP-1 drugs used to treat diabetes and for weight loss — and that the ...

The calls come thick and fast to Mumbai-based diabetologist Rahul Baxi - but not just from patients struggling to control blood sugar. Increasingly, it is young professionals asking the same thing: ...

Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults ...